Biofarm (stock symbol BIO), one of Romania's leading drug manufacturers, recorded a net profit of 69.9 million lei in the first nine months of the year, up 6% compared to the same period last year. Turnover increased by 10% to 229 million lei, compared to 209 million lei in 2022. EBITDA reached 81.6 million lei.
"The results achieved in the first nine months of 2023 confirm our long-term development strategy. Even though the CHC market as a whole is experiencing a decrease in consumption, Biofarm manages to record growth in consumption and thus we are strengthening our position in CHC by protecting the top brands in our portfolio and by maintaining investments at a competitive level in CHC categories with high business potential. We will continue to focus on developing new solutions for patients' health, to meet their needs and to honour the company's mission of doing good for those around us through continuous improvement," said Cătălin Vicol, Biofarm CEO.
In the first nine months of 2023, Biofarm ranked 2nd in the Consumer Healthcare (CHC) segment in terms of units sold. In value terms, the company strengthened its sales to end consumers, recording an increase of more than 15% compared to the first nine months of 2022, based on the purchase price in pharmacies.
The therapeutic areas with the highest absolute growth in value in the first nine months of the year in which Biofarm is active were cold & flu, pain, magnesium-based supplements, digestion, and nasal decongestants. Biofarm brands associated with these therapeutic areas have seen increases in value market share.
The continuous development of new products, constantly adapted to the needs of consumers in continuous diversification, is one of Biofarm's pillars of growth. The company is also the volume market leader in the reference categories of 8 of its brands: Bixtonim, Colebil, Triferment, Sennalax, Extravalerianic, Carmol solution, Carbocit and Nervocalmin. This balanced mix of long-lasting brands and innovation is a strong differentiator for Biofarm's portfolio, positioning the company among the most relevant players in the CHC category.
Biofarm has invested more than 44 million euros so far in one of the most modern drug factories in Romania, which covers an impressive area of more than 10,000 square meters and has four production streams, specializing in tablets, film-coated tablets, dragees, soft capsules, solutions and syrups. This state-of-the-art plant is a key element in achieving the company's strategic objectives, which include portfolio development through line extensions, new product launches and expansion into foreign markets.
The information provided by KomuniK
DN Agrar Group (BVB: DN), one of the leading integrated agrifood companies in Romania and the largest dairy milk producer in Europe, reported record results for the first nine months of 2025. The company achieved a turnover of RON 158 million, a 25% increase year-on-year, while net profit doubled to RON 43 million, backed by […]
Presidential adviser Ludovic Orban is leaving his position after just six weeks in office, following a mutual agreement with president Nicușor Dan to end their collaboration, the Presidential Administration announced on Tuesday, November 18, as reported by Agerpres. Orban, a former prime...
Yellow Fresh Fruits has quickly emerged as one of Romania’s most dynamic fresh fruit importers, reshaping a market where consistency and speed increasingly define competitiveness. In an interview with Romania Insider, Fryderyk Schiller, COO of Yellow Fresh Fruits, outlines how the company expanded from its Polish origins to operating advanced ripening centers in Timișoara, Bucharest, […]
The design phase for the most difficult section of the A8 highway, namely Lot 2B Grinţieş-Pipirig, has begun, according to a statement given by Romanian transport minister Ciprian Şerban on Monday, November 18. The contract for the section, valued at RON 5.97 billion (EUR 1.17 billion), was signed at the end of October. In total, […]
The Board of Directors convenes the Ordinary General Meeting of Shareholders on December 18/19, 2025 The Board of Directors of EVERGENT Investments, an investment company listed under the ticker EVER, has convened the Ordinary General Meeting of Shareholders for December 18/19, 2025. The proposal submitted for shareholders’ approval is the distribution of dividends from reserves […]
City Grill Group surpasses EUR 63.5 million in revenue in the first 10 months With one in six people affected by loneliness, according to the WHO, restaurants are once again becoming essential spaces for reconnection, and dining out is reclaiming its role as an authentic social experience. City Grill Group, the largest Romanian-owned restaurant chain, […]
